Titre :
|
Safety of Revaccination with pneumococcal polysaccharide vaccine. (1999)
|
Auteurs :
|
L.A. JACKSON ;
P. BENSON ;
J.C. BUTLER ;
G. CARLONE ;
R.T. CHEN ;
F. DESTEFANO ;
P. HOLDER ;
L.S. LEWIS ;
T. LEZHAVA ;
V.P. SNELLER ;
R.S. THOMPSON ;
W.W. Williams ;
Centers for Disease Control and Prevention. Atlanta. GA. USA ;
Immunization Studies Program. Center for Health Studies. Group Health Cooperative of Puget Sound. Seattle. USA
|
Type de document :
|
Article
|
Dans :
|
JAMA - Journal of the american medical association (vol. 281, n° 3, 1999)
|
Pagination :
|
243-248
|
Langues:
|
Anglais
|
Mots-clés :
|
Streptococcie
;
Bactériose
;
Infection
;
Etude comparée
;
Prévention santé
;
Effet secondaire
;
Recommandation
;
Homme
;
Personne âgée
|
Résumé :
|
[BDSP. Notice produite par INIST P3ErR0xH. Diffusion soumise à autorisation]. Context Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several years of first vaccination has been associated with a higher than expected frequency and severity of local injection site reactions. The risk of adverse events associated with revaccination of elderly and chronically ill persons 5 or more years after first vaccination, as is currently recommended, has not been well defined. Objective To determine whether revaccination with PPV at least 5 years after first vaccination is associated with more frequent or more serious adverse events than those following first vaccination. Design Comparative intervention study conducted between April 1996 and August 1997. Participants Persons aged 50 to 74 years either who had never been vaccinated with PPV (n=901) or who had been vaccinated once at least 5 years prior to enrollment (n=513). Intervention PPV vaccination. Main Outcome Measures Postvaccination local injection site reactions and prevaccination concentrations of type-specific antibodies. Results Those who were revaccinated were more likely than those who received their first vaccinations to report a local injection site reaction of at least 10.2 cm (4 in) in diameter within 2 days of vaccination : 11% (55/513) vs 3% (29/901) (relative risk [RR], 3.3 ; 95% confidence interval [Cl], 2.1-5.1). These reactions resolved by a median of 3 days following vaccination. (...)
|